These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 17230226

  • 21. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
    O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.
    Blood; 2003 May 01; 101(9):3597-605. PubMed ID: 12531805
    [Abstract] [Full Text] [Related]

  • 22. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel WE, Serve H.
    Blood; 2000 Dec 01; 96(12):3907-14. PubMed ID: 11090077
    [Abstract] [Full Text] [Related]

  • 23. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
    Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J.
    Blood; 2003 Jul 15; 102(2):646-51. PubMed ID: 12663439
    [Abstract] [Full Text] [Related]

  • 24. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, Fox CJ, Thompson CB, Cools J, Schwaller J.
    Cancer Res; 2006 Apr 01; 66(7):3828-35. PubMed ID: 16585210
    [Abstract] [Full Text] [Related]

  • 25. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A, Marz S, Rushton S, Holzwarth C, Lind K, Kayser S, Döhner K, Peschel C, Oostendorp RA, Götze KS.
    Cancer Res; 2011 Jul 01; 71(13):4696-706. PubMed ID: 21546568
    [Abstract] [Full Text] [Related]

  • 26. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.
    Dtsch Med Wochenschr; 2002 Oct 18; 127(42):2195-200. PubMed ID: 12397548
    [Abstract] [Full Text] [Related]

  • 27. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
    Kohl TM, Hellinger C, Ahmed F, Buske C, Hiddemann W, Bohlander SK, Spiekermann K.
    Leukemia; 2007 Aug 18; 21(8):1763-72. PubMed ID: 17554384
    [Abstract] [Full Text] [Related]

  • 28. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G.
    Exp Hematol; 2007 Apr 18; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [Abstract] [Full Text] [Related]

  • 29. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
    Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel WE, Serve H.
    Cancer Res; 2005 Nov 01; 65(21):9643-50. PubMed ID: 16266983
    [Abstract] [Full Text] [Related]

  • 30. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
    Skwarska A, Augustin E, Beffinger M, Wojtczyk A, Konicz S, Laskowska K, Polewska J.
    Biochem Pharmacol; 2015 Jun 15; 95(4):238-52. PubMed ID: 25896848
    [Abstract] [Full Text] [Related]

  • 31. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.
    Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T.
    Oncogene; 2002 Apr 11; 21(16):2555-63. PubMed ID: 11971190
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E, Barbarroja N, Torres LA, Buendía P, Velasco F, Dorado G, Torres A, López-Pedrera C.
    Hematol Oncol; 2007 Mar 11; 25(1):30-7. PubMed ID: 17128418
    [Abstract] [Full Text] [Related]

  • 33. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
    Köthe S, Müller JP, Böhmer SA, Tschongov T, Fricke M, Koch S, Thiede C, Requardt RP, Rubio I, Böhmer FD.
    J Cell Sci; 2013 Oct 15; 126(Pt 20):4746-55. PubMed ID: 23943874
    [Abstract] [Full Text] [Related]

  • 34. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S, Boutzen H, David L, Larrue C, Vergez F, Fernandez-Vidal A, Yuan L, Hospital MA, Tamburini J, Demur C, Delabesse E, Saland E, Sarry JE, Galcera MO, Mansat-De Mas V, Didier C, Dozier C, Récher C, Manenti S.
    Oncotarget; 2015 Nov 10; 6(35):38061-78. PubMed ID: 26515730
    [Abstract] [Full Text] [Related]

  • 35. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
    Yao Q, Nishiuchi R, Kitamura T, Kersey JH.
    Leukemia; 2005 Sep 10; 19(9):1605-12. PubMed ID: 16034464
    [Abstract] [Full Text] [Related]

  • 36. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.
    Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D.
    Leukemia; 2002 Oct 21; 16(10):2027-36. PubMed ID: 12357354
    [Abstract] [Full Text] [Related]

  • 38. Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation.
    Razumovskaya E, Masson K, Khan R, Bengtsson S, Rönnstrand L.
    Exp Hematol; 2009 Aug 21; 37(8):979-89. PubMed ID: 19477218
    [Abstract] [Full Text] [Related]

  • 39. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A, Oshikawa G, Okada K, Fukutake S, Umezawa Y, Nagao T, Kurosu T, Miura O.
    Oncotarget; 2015 Apr 20; 6(11):9189-205. PubMed ID: 25826077
    [Abstract] [Full Text] [Related]

  • 40. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
    Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M, Carter GI, Grundy M, Shang S, Russell NH.
    Leukemia; 2006 Dec 20; 20(12):2130-6. PubMed ID: 17066094
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.